Brief: Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
21/01/2026 13:46
Jan 21 (Reuters) - Actuate Therapeutics Inc ACTU.O: ACTUATE THERAPEUTICS ANNOUNCES PLANS TO EXPAND CLINICAL PIPELINE, ADVANCING ELRAGLUSIB TABLET INTO A PHASE 1/2 CLINICAL PROGRAM IN REFRACTORY CANCERS ACTUATE THERAPEUTICS INC: INITIATION OF PHASE 1 PORTION OF TRIAL PLANNED IN 2H 2026 Source text: ID:nGNXbYcDk0 Further company coverage: ACTU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actuate Therapeutics
See all newsHealth Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Brief: Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
Brief: Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing
Brief: Actuate Therapeutics Announces Positive Patient Outcomes From Phase 1 Trial
Brief: Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC Filing